Evidence map›Paper›PMID 33077869›Full record

ArticleLeukemia2021

Repolarization of HSC attenuates HSCs failure in Shwachman-Diamond syndrome.

Sachin Kumar, Kalpana J Nattamai, Aishlin Hassan, Amanda Amoah, Rebekah Karns, Cuiping Zhang, Ying Liang, Akiko Shimamura, M Carolina Florian, Ute Bissels and 6 more

Open access · greenAbstract read
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. tRNA mNature communications · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Sachin KumarDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Research Foundation, Cincinnati, OH, 45229, USA.
Kalpana J NattamaiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Research Foundation, Cincinnati, OH, 45229, USA.
Aishlin HassanDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Research Foundation, Cincinnati, OH, 45229, USA.
Amanda AmoahInstitute of Molecular Medicine, Ulm University, Ulm, Germany.ORCID http://orcid.org/0000-0002-1267-4091
Rebekah KarnsDivision of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, USA.
Cuiping ZhangDepartment of Toxicology and Cancer Biology, University of Kentucky, Health Sciences Research Building, Room 340, 1095 V.A. Drive, Lexington, KY, 40536, USA.
Ying LiangDepartment of Toxicology and Cancer Biology, University of Kentucky, Health Sciences Research Building, Room 340, 1095 V.A. Drive, Lexington, KY, 40536, USA.
Akiko ShimamuraBoston Children's Hospital, Dana Farber Cancer Institute, Boston, MA, USA.
M Carolina FlorianInstitute of Molecular Medicine, Ulm University, Ulm, Germany.ORCID http://orcid.org/0000-0002-5791-1310
Ute BisselsMiltenyi Biotec GmbH, Bergisch Gladbach, Germany.
Martha LuevanoMiltenyi Biotec GmbH, Bergisch Gladbach, Germany.
Andreas BosioMiltenyi Biotec GmbH, Bergisch Gladbach, Germany.
Stella M DaviesDivision of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Medhanie MulawInstitute of Experimental Cancer Research, Ulm University, Ulm, Germany.ORCID http://orcid.org/0000-0002-2501-6952
Hartmut Geiger *Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Research Foundation, Cincinnati, OH, 45229, USA. hartmut.geiger@me.com.ORCID http://orcid.org/0000-0002-5794-5430
Kasiani C Myers *Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. kasiani.myers@cchmc.org.ORCID http://orcid.org/0000-0002-5528-4405
Cincinnati Children's Hospital Medical Center · USMiltenyi Biotec (Germany) · DEUniversität Ulm · DEUniversity of Kentucky · USBoston Children's Hospital · US

Funding

Pediatric Center--Gene Expression /Developmental ScienceK12HD028827 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI Tina Lee Cheng · 2002 to 2026
$9.6M
Systems Biology of Bone Marrow Failure and MDS for Precision MedicineRC2DK122533 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI FIGUEROA, MARIA EUGENIA, FLEMING, MARK D · 2019 to 2023
$6.4M
Cdc42, hematopoietic stem cell polarity, and cell fateR01DK104814 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI ZHENG, YI · 2016 to 2019
$2.0M
NICHD NIH HHS K12 HD028827NIDDK NIH HHS R01 DK104814NIDDK NIH HHS RC2 DK122533
6 · The paper itself

Abstract

Shwachman-Diamond syndrome (SDS) is a bone marrow failure (BMF) syndrome associated with an increased risk of myelodysplasia and leukemia. The molecular mechanisms of SDS are not fully understood. We report that primitive hematopoietic cells from SDS patients present with a reduced activity of the small RhoGTPase Cdc42 and concomitantly a reduced frequency of HSCs polar for polarity proteins. The level of apolarity of SDS HSCs correlated with the magnitude of HSC depletion in SDS patients. Importantly, exogenously provided Wnt5a or GDF11 that elevates the activity of Cdc42 restored polarity in SDS HSCs and increased the number of HSCs in SDS patient samples in surrogate ex vivo assays. Single cell level RNA-Seq analyses of SDS HSCs and daughter cells demonstrated that SDS HSC treated with GDF11 are transcriptionally more similar to control than to SDS HSCs. Treatment with GDF11 reverted pathways in SDS HSCs associated with rRNA processing and ribosome function, but also viral infection and immune function, p53-dependent DNA damage, spindle checkpoints, and metabolism, further implying a role of these pathways in HSC failure in SDS. Our data suggest that HSC failure in SDS is driven at least in part by low Cdc42 activity in SDS HSCs. Our data thus identify novel rationale approaches to attenuate HSCs failure in SDS.

Indexed as

Cell PolarityBone Marrow CellsBone Morphogenetic Proteinscdc42 GTP-Binding ProteinCells, CulturedGrowth Differentiation FactorsHematopoietic Stem CellsHumansPrognosisShwachman-Diamond SyndromeWnt-5a ProteinBone Morphogenetic Proteinscdc42 GTP-Binding ProteinCDC42 protein, humanGDF11 protein, humanGrowth Differentiation FactorsWnt-5a ProteinWNT5A protein, human

Identifiers

PMID33077869
PMCPMC11334678
OpenAlexW3093224465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.